Monsanto v Bowman: Supreme Court rejects “blame-the-bean” defence
The US Supreme Court has decided unanimously in favour of agricultural company Monsanto in its patent battle against Indiana farmer Vernon Bowman.
AstraZeneca loses Seroquel appeal
The UK Court of Appeal has upheld the High Court’s decision that AstraZeneca’s patent for a sustained release formulation of anti-psychotic drug quetiapine is invalid.
Pfizer sells Viagra online to curb counterfeit trade
Pfizer has announced it will sell its erectile dysfunction pill Viagra online in an effort to counter the rising threat of bogus online pharmacies.
Acura sues Ranbaxy over abuse-resistant generic
Acura Pharmaceuticals has sued Ranbaxy Laboratories to keep it from releasing a generic version of its immediate release tablet formulation of painkiller Oxecta.
Cyclacel sells cancer drug patents to Celgene
Cyclacel Pharmaceuticals has entered into a definitive agreement to sell four of its patents related to the use of the romidepsin injection to Celgene Corporation.
Baker & McKenzie Mexico hires life sciences head
Baker & McKenzie has hired Christian Alejandro López-Silva as head of its pharmaceutical and life sciences group in Mexico.
Actavis eyes $100 million after OxyContin settlement
Generic drug-maker Actavis believes it will earn profits of around $100 million in the next two years from licensing patents owned by Purdue Pharma LP.
Orchid invests in new European pharma
Indian pharmaceutical company Orchid Chemicals and Pharmaceuticals has entered into a partnership with new European biopharmaceutical company Allecra Therapeutics.
FTC critical of pay-for-delay in annual report
The US Federal Trade Commission has published its annual report for 2012, in which it remains critical of “pay-for-delay” patent settlements.
Shionogi sues Hospira to block Doribax generic
Japanese pharma Shionogi has brought a lawsuit against Hospira Inc to keep it from marketing a generic version of Shionogi’s Doribax, alleging it infringes one of the company’s patents.
